These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Current state and advances in desensitization for peanut allergy in pediatric age. Foti Randazzese S; Panasiti I; Caminiti L; Catamerò F; Landi M; De Filippo M; Votto M; Olcese R; Favuzza F; Giovannini M; Barberi S Pediatr Allergy Immunol; 2024 Apr; 35(4):e14127. PubMed ID: 38646959 [TBL] [Abstract][Full Text] [Related]
5. Current Trend in Immunotherapy for Peanut Allergy. Joo Chan C; Richardo T; Lim RLH Int Rev Immunol; 2018; 37(6):279-290. PubMed ID: 30638084 [TBL] [Abstract][Full Text] [Related]
6. Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts. Berin MC; Agashe C; Burks AW; Chiang D; Davidson WF; Dawson P; Grishin A; Henning AK; Jones SM; Kim EH; Leung DYM; Masilamani M; Scurlock AM; Sicherer SH; Wood RA; Sampson HA J Allergy Clin Immunol; 2022 Apr; 149(4):1373-1382.e12. PubMed ID: 34653515 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy. Dupont C; Burks AW; Fleischer DM; Bee KJ; Chainani S; Sampson HA Expert Rev Clin Immunol; 2024 Jun; 20(6):623-633. PubMed ID: 38323337 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. O'B Hourihane J; Beyer K; Abbas A; Fernández-Rivas M; Turner PJ; Blumchen K; Nilsson C; Ibáñez MD; Deschildre A; Muraro A; Sharma V; Erlewyn-Lajeunesse M; Zubeldia JM; De Blay F; Sauvage CD; Byrne A; Chapman J; Boralevi F; DunnGalvin A; O'Neill C; Norval D; Vereda A; Skeel B; Adelman DC; du Toit G Lancet Child Adolesc Health; 2020 Oct; 4(10):728-739. PubMed ID: 32702315 [TBL] [Abstract][Full Text] [Related]
9. Peanut Allergen Powder-dnfp: A Novel Oral Immunotherapy to Mitigate Peanut Allergy. Dougherty JA; Wagner JD; Stanton MC Ann Pharmacother; 2021 Mar; 55(3):344-353. PubMed ID: 32718178 [TBL] [Abstract][Full Text] [Related]
16. Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies. DunnGalvin A; Fleischer DM; Campbell DE; O'B Hourihane J; Green TD; Sampson HA; Greenhawt M J Allergy Clin Immunol Pract; 2021 Jan; 9(1):216-224.e1. PubMed ID: 32841748 [TBL] [Abstract][Full Text] [Related]
17. Peanut Allergy: Changes in Dogma and Past, Present, and Future Directions. Boudreau-Romano S; Qamar N Pediatr Ann; 2018 Jul; 47(7):e300-e304. PubMed ID: 30001445 [TBL] [Abstract][Full Text] [Related]
18. Food allergy immunotherapy: Oral immunotherapy and epicutaneous immunotherapy. Kim EH; Burks AW Allergy; 2020 Jun; 75(6):1337-1346. PubMed ID: 32034781 [TBL] [Abstract][Full Text] [Related]
19. Dose and route of administration determine the efficacy of prophylactic immunotherapy for peanut allergy in a Brown Norway rat model. Sztuk TKS; Rigby NM; Nørskov-Nielsen L; Koppelman SJ; Sancho AI; Knudsen NH; Marsh J; Johnson P; Gupta S; Mackie AR; Larsen JM; Bøgh KL Front Immunol; 2023; 14():1121497. PubMed ID: 36911669 [TBL] [Abstract][Full Text] [Related]
20. Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy. Fernandez-Rivas M; Vereda A; Vickery BP; Sharma V; Nilsson C; Muraro A; Hourihane JO; DunnGalvin A; du Toit G; Blumchen K; Beyer K; Smith A; Ryan R; Adelman DC; Jones SM Allergy; 2022 Mar; 77(3):991-1003. PubMed ID: 34320250 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]